Schweinfurthin analogues

Abstract

Methods and intermediates for preparing enantiomerically enriched Schweinfurthin analogs which are useful for the treatment of cancer, as well as novel Schweinfurthin analogs having anti-cancer activity, compositions comprising such analogs and therapeutic methods comprising administering such analogs.

1 . A compound of formula (XX): 
       
         
           
           
               
               
           
         
       
       wherein:
 R 7  and R 8  are each independently H or (C 1 -C 6 )alkyl; 
 R 9  is H, (C 1 -C 15 )alkyl, (C 2 -C 15 )alkenyl, (C 2 -C 15 )alkynyl, (C 1 -C 15 )alkoxy, (C 1 -C 15 )alkanoyl, (C 1 -C 15 )alkoxycarbonyl, (C 2 -C 15 )alkanoyloxy, aryl or heteroaryl, which aryl or heteroaryl is optionally substituted with one or more halo, hydroxy, cyano, CF 3 , OCF 3 , NR a R b , (C 1 -C 15 )alkyl, (C 2 -C 15 )alkenyl, (C 2 -C 15 )alkynyl, (C 1 -C 15 )alkoxy, (C 1 -C 15 )alkanoyl, (C 1 -C 15 )alkoxycarbonyl, (C 1 -C 15 )alkoxy(C 1 -C 15 )alkoxy, —P(═O)(OH) 2 , and (C 2 -C 15 )alkanoyloxy; 
 R 10  is H or (C 1 -C 6 )alkyl; and 
 R a  and R b  are each independently H or (C 1 -C 6 )alkyl 
 wherein any (C 1 -C 15 )alkyl, (C 2 -C 15 )alkenyl, (C 2 -C 15 )alkynyl, (C 1 -C 15 )alkoxy, (C 1 -C 15 )alkanoyl, (C 1 -C 15 )alkoxycarbonyl, or (C 2 -C 15 )alkanoyloxy of R 7 , R 8 , and R 9  is optionally substituted with one or more halo, hydroxy, cyano, or oxo (═O). 
 or a pharmaceutically acceptable salt thereof. 
 
     
     
         2 . The compound of  claim 1  wherein R 7  is H. 
     
     
         3 . The compound of  claim 1  wherein R 7  is (C 1 -C 6 )alkyl. 
     
     
         4 . (canceled) 
     
     
         5 . The compound of  claim 1  wherein R 8  is H. 
     
     
         6 . The compound of  claim 1  wherein R 8  is (C 1 -C 6 )alkyl. 
     
     
         7 . (canceled) 
     
     
         8 . The compound of  claim 1  wherein R 9  is H. 
     
     
         9 . The compound of  claim 1  wherein R 9  is (C 1 -C 15 )alkyl, (C 2 -C 15 )alkenyl, (C 2 -C 15 )alkynyl, (C 1 -C 15 )alkoxy, (C 1 -C 15 )alkanoyl, (C 1 -C 15 )alkoxycarbonyl, (C 2 -C 15 )alkanoyloxy. 
     
     
         10 . (canceled) 
     
     
         11 . The compound of  claim 1  wherein R 9  is aryl optionally substituted with one or more halo, hydroxy, cyano, CF 3 , OCF 3 , NR a R b , (C 1 -C 15 )alkyl, (C 2 -C 15 )alkenyl, (C 2 -C 15 )alkynyl, (C 1 -C 15 )alkoxy, (C 1 -C 15 )alkanoyl, (C 1 -C 15 )alkoxycarbonyl, and (C 2 -C 15 )alkanoyloxy. 
     
     
         12 . The compound of  claim 1  wherein R 9  is aryl optionally substituted with one or more halo, hydroxy, cyano, CF 3 , OCF 3 , NR a R b , (C 2 -C 15 )alkenyl, (C 2 -C 15 )alkynyl, (C 1 -C 15 )alkoxy, (C 1 -C 15 )alkanoyl, (C 1 -C 15 )alkoxycarbonyl, and (C 2 -C 15 )alkanoyloxy. 
     
     
         13 . The compound of  claim 1  wherein R 9  is aryl optionally substituted with one or more halo, hydroxy, cyano, CF 3 , OCF 3 , NR a R b , (C 2 -C 15 )alkenyl, (C 1 -C 15 )alkoxy. 
     
     
         14 . The compound of  claim 11  wherein aryl is phenyl or naphthyl. 
     
     
         15 . The compound of  claim 1  wherein R 9  is of the formula 
       
         
           
           
               
               
           
         
       
       wherein:
 R c  and R e  are each independently H, halo, hydroxy, (C 1 -C 15 )alkyl, (C 2 -C 15 )alkenyl, (C 2 -C 15 )alkynyl, (C 1 -C 15 )alkoxy, methoxymethoxy, and (C 2 -C 15 )alkanoyloxy; and 
 R d  is H, (C 1 -C 15 )alkyl, (C 2 -C 15 )alkenyl, (C 2 -C 15 )alkynyl, (C 1 -C 15 )alkoxy, (C 1 -C 15 )alkanoyl, (C 1 -C 15 )alkoxycarbonyl, and (C 2 -C 15 )alkanoyloxy; 
 wherein any (C 1 -C 15 )alkyl, (C 2 -C 15 )alkenyl, (C 2 -C 15 )alkynyl, (C 1 -C 15 )alkoxy, (C 1 -C 15 )alkanoyl, (C 1 -C 15 )alkoxycarbonyl, or (C 2 -C 15 )alkanoyloxy of R c , R e , and R d  is optionally substituted with one or more halo, hydroxy, cyano, or oxo (═O). 
 
     
     
         16 . The compound of  claim 1  wherein R 9  is of the formula 
       
         
           
           
               
               
           
         
       
       wherein:
 R c  and R e  are each independently H, halo, hydroxy, (C 1 -C 15 )alkyl, (C 2 -C 15 )alkenyl, (C 2 -C 15 )alkynyl, (C 1 -C 15 )alkoxy, methoxymethoxy, and (C 2 -C 15 )alkanoyloxy; and 
 R d  is H, (C 1 -C 15 )alkyl, (C 2 -C 15 )alkenyl, (C 2 -C 15 )alkynyl, (C 1 -C 15 )alkoxy, (C 1 -C 15 )alkanoyl, (C 1 -C 15 )alkoxycarbonyl, and (C 2 -C 15 )alkanoyloxy; 
 R g  is H, cyano, fluoro, or —P(═O)(OH) 2 ; and 
 R h  is H, cyano, fluoro, or or —P(═O)(OH) 2 ; 
 wherein any (C 1 -C 15 )alkyl, (C 2 -C 15 )alkenyl, (C 2 -C 15 )alkynyl, (C 1 -C 15 )alkoxy, (C 1 -C 15 )alkanoyl, (C 1 -C 15 )alkoxycarbonyl, or (C 2 -C 15 )alkanoyloxy of R c , R e , and R d  is optionally substituted with one or more halo, hydroxy, cyano, or oxo (═O). 
 
     
     
         17 . The compound of  claim 6  wherein R c  and R e  are each independently H, fluoro, chloro, bromo, hydroxy, or methoxy. 
     
     
         18 . The compound of  claim 6  wherein at least one of R c  and R e  is hydroxy. 
     
     
         19 . The compound  claim 16  wherein R d  is (C 2 -C 15 )alkenyl optionally substituted with one or more halo, hydroxy, or oxo (═O). 
     
     
         20 . The compound of  claim 16  wherein R d  is hydrogen, trans-3,7-dimethyl-2,6-octadien-1-yl, or trans-3,7-dimethyl-8-hydroxy-2,6-octadien-1-yl. 
     
     
         21 . The compound of  claim 1  wherein R 9  is isoxazolyl, imadazolyl, pyridyl, indolyl, or benzo[b]furanyl. 
     
     
         22 . (canceled) 
     
     
         23 . A pharmaceutical composition comprising a compound as described in  claim 1  and a pharmaceutically acceptable carrier. 
     
     
         24 . A method for treating cancer comprising administering a therapeutically effective amount of a compound as described in  claim 1  to a mammal. 
     
     
         25 . (canceled)